An interventional study of BD211 Drug Product in Hematologic Diseases, sponsored by Shanghai BDgene Co., Ltd.. Completed at 1 site in China. Open to participants aged 5 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-05-18.
Sponsored by Shanghai BDgene Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Hematologic Diseases with a site in China — 19 open to participants now, 25 under way, 8 of them phase 3. Hematologic Diseases · China.
Among the 65 studies in Hematologic Diseases with a site in China, this one is the 51st largest by enrollment of the 52 interventional ones that give a count, is one of 9 that started in 2021, is one of 12 with no phase, and was the 26th registered.
610 studies on the registry are indexed under Hematologic Diseases; 109 are open to participants now.
Browse Hematologic Diseases studies →19 of the 65 studies in Hematologic Diseases with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Xiamen University · Sites in China
Liping Dou · Sites in China
Ages 18+
The General Hospital of Western Theater Command · Sites in China
Ages 18+
Zhejiang University · Sites in China
Ages 18+
Anhui Provincial Hospital · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 73 Hematologic Diseases studies recruiting now, 46 (63%) set no upper age limit and 23 (32%) stop at 75 or younger; 28 take children under 18; 4 take healthy volunteers.
This study: 5 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 16 · Phase 3 14 · Phase 4 2
First in 2003; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 50 across 411 interventional studies indexed under Hematologic Diseases.
Median enrollment 62 across the 52 interventional studies, 300 across the 13 observational. Of the 26 that completed or were terminated, 8 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 65 have an industry lead sponsor. The 10 most frequent:
Shanghai BDgene Co., Ltd. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
Shanghai BDgene Co., Ltd. has 1 study filed under Hematologic Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Hematologic Diseases with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT07483385The General Hospital of Western Theater CommandEfficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation | 2027-01-28 |
| NCT06548958The First Affiliated Hospital of Soochow UniversityA Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases | 2027-03-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 65 studies in Hematologic Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1,open label,safety,and efficacy study in subjects with non-β0/β0 TDT β-thalassemia Major by transplanting BD211 drug product which is for autologous use only,via a single IV administration.
After collection of mobilised peripheral blood samples, the patient's autologous cells,enriched for CD34+ HSCs, undergo ex vivo transduction with lentiviral vector encoding βA-T87Q-globin to BD211 finished product,which is then infused intravenously into the patient after myeloablative busulfan conditioning to prepare bone marrow "niches" for engraftment of the HSCs.
After discharge, subjects will be followed monthly, at a minimum, for 6 months and thereafter every 3 months for the remainder of the 24 months post-transplant.
Evaluation will include Routine and special biological testing at regular intervals, collection of AEs and concomitant medications, and evaluation of disease specific biological and clinical parameters.
Subjects will then be enrolled in a long-term follow-up protocol with annual evaluations for an additional 13 years post-transplant.
The long-term follow-up study will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.
This study will end when the last subject completes the Month 24 visit or discontinues from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will participate in this study for a total of approximately 27 months, consisting of an up to 3 months pre-transplant period(consisting of a screening period followed by autologous cell harvest, followed by a waiting period during which the harvested cells are transduced and undergo release testing, followed by treatment with busulfan IV, and a single infusion of BD211 Drug Product) and a 24-month post-transplant evaluation period. Following completion of this study, all subjects will be asked to provided consent to participate in a follow-up study for another 13 years, which will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.
Genetic: BD211 Drug Product
Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.
Evaluate the success and kinetics of HSC engraftment.
Three consecutive absolute neutrophil counts≥500 cells/uL, three consecutive platelet values ≥20 e9/L, measure blood samples monthly after BD211 drug product infusion.
Time frame: At multiple timepoints after infusion for 24 months.
Incidence of transplant-related mortality through 100 days post-transplant.
Incidence of transplant-related mortality through 100 days post-transplant.
Time frame: Up to 100 days post-HSCT.
Overall survival of maintenance phase.
Overall survival up to 24 months post-HSCT.
Time frame: Up to 24 months post-HSCT.
Post-transplant blood samples for replication competent lentivirus (RCL) testing.
The testing of any subject positivity will be considered an SAE and suspend the inclusion of new subjects.
Time frame: At multiple timepoints after infusion for 24 months.
Assessment of Clonal dominance or leukemia/lymphoma and other malignancies.
Using peripheral blood of subjects for integration site analysis via LAM-PCR \& deep sequencing.
Time frame: At multiple timepoints after infusion for 24 months.
Incidence of treatment- related adverse events.
According to the requirements of the National Cancer Institute Common Terminology Standards for Adverse Events (NCI CTCAE) version 5.0, monitor laboratory parameters and the frequency and severity of clinical AEs.
Time frame: Up to 24 months after BD211 drug product infusion.
Quantify gene transfer efficiency and expression of BD211 drug product.
Expression of βA-T87Q-globin chain in whole blood by assessing the ratio of βA-T87Q-globin to α-globin, as well as βA-T87Q-globin fractions in all β-chains over time by HPLC.
Time frame: Up to 24 months after engraftment.
Quantify the hematopoietic chimerism resulting from treatment with BD211 drug product.
Measuring lentiviral vector copy number per diploid genome(c/dg) for evaluation.
Time frame: Up to 24 months after engraftment.
HbAT87Q in peripheral blood
Measure the effects of transplantation with BD211 on the expression of disease-specific biological parameters and clinical events, including amounts of HbAT87Q in peripheral blood in grams per deciliter (g/dL).
Time frame: Up to 24 months after engraftment.
Reduction of RBC transfusion requirements from baseline
Reduction from baseline of RBC transfusion requirements (mL/kg) per month and year post-transplant, Up to 24 months after engraftment.
Time frame: Up to 24 months after engraftment.
Duration of transfusion independence (months).
Duration of transfusion independence up to 24 months after engraftment.
Time frame: Up to 24 months after engraftment.
Weighted average Hemoglobin
Weighted average Hemoglobin during transfusion independence in grams per deciliter (g/dL), up to 24 months after engraftment.
Time frame: Up to 24 months after engraftment.
Changes of liver iron burden from baseline
Changes from baseline in iron burden by assessing liver iron content (mg Fe/g dry weight).
Time frame: Up to 24 months after engraftment.
Changes of cardiac iron burden from baseline
Changes from baseline in iron burden by assessing cardiac iron content using magnetic resonance imaging (MRI) T2\* value (milliseconds, ms).
Time frame: Up to 24 months after engraftment.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2021 to primary completion in Aug 2024, 37 months.
Of 54 interventional studies with no phase under Hematologic Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 47. This study's 37 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai BDgene Co., Ltd.